Recent advances in the development of a non-peptide δ opioid analgesic

Pharmacology Reviews and Communications

Volumn 9, Issue 1-2, 1997, Pages 49-60

  Clarke, Geoffrey D ^a   Dondio, G Massimo ^a  

^a SmithKline Beccham SpA   (Italy)

Author keywords

Delta opioid analgesic; Drug development; Non peptide drugs; Opioid receptors

Indexed keywords

EID: 26444458449     PISSN: 10288945     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Zenz, M. and Willweber-Strumpf, A. (1993). Opiophobia and cancer pain in Europe, Lancet, 341, 1075-1076.
2. Fortenoy, R. K. (1994). Opioid therapy for chronic non-malignant pain: current status. In: Progress in Pain Research and Management vol. 1, eds. H. L. Fields and J. C. Liebeskind. IASP Press, Seattle.
3. Martin, W. R., Eades, G. C., Thompson, J. A., Huppler, R. E. and Gilbert, P. E. (1976). The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog, J. Pharm. Exp. Ther., 197 (3), 517-532.
4. Lord, J. A., Waterfield, A. A., Hughes, J. and Kosterlitz, H. W. (1977). Endogenous opioid peptides: multiple agonists and receptors, Nature, 267, 495-499.
5. Goldstein, A., Lowney, L. I. and Pal, B. K. (1971). Sterospecific and nonspecific interactions of the morphine congener levorphanol in subsecellular fractions of mouse brain, Proc. Natl. Acad. Sci. USA, 68, 1742-1747.
6. Leslie, F. M. (1987). Methods used for the study of opioid receptors, Pharmacol. Rev., 39 (3), 197-249.
7. Hammond, D. (1993). Pharmacological mechanisms of pain modulation, In: Current and Emerging Issues in Cancer Pain: Research and Practice, eds. C. R. Chapman and K. M. Foley, Raven Press, Ltd, New York, 175-183.
8. Millan, M. J. (1990). κ-Opioid receptors and analgesia, TIPS, 11, 70-76.
9. Rapaka, R. S. and Porreca, F. (1991). Development of delta opioid peptides as nonaddicting analgesics, Pharm. Res., 8 (1), 1-8.
10. VonVoigtlander, P. F., Lahti, R. A. and Ludens, J. H. (1983). U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist, J. Pharm. Exp. Ther., 224 (1), 7-12.
11. Giardina, G., Colle, R. and Vecchietti, V. (1991). Selective, non-peptidic kappa-opioid agonists, Current Opinion in Therapeutic Patents, 1(3), 345-362.
12. Dionne, R. A., Dobbins, K. R., Hargreaves, K. M. (1991). Evaluation of a kappa opioid agonist, spiradoline, in comparison to morphine and placebo in the oral surgery model, Clin. Pharm. Ther., 49, 183.
13. Peters, G. R. and Gaylor, S. (1989). Human central nervous system (CNS) effects of a selective κ opioid agonist, Clin. Pharmacol. Ther., 45, 130.
14. Dawkins, R., Lebsack, M. E., Wright, D. S. and Posvar, E. L. (1991). Rising, Single dose tolerance, pharmacokinetics and pharmacodynamics of intramuscular CI-977, J. Clin. Pharmacol., 31, 864.
15. Coltro Campi, C. and Clarke, G. D. (1995). Effects of highly selective kappa opioid agonists on EEG power spectra and behavioural correlates in conscious rats, Pharmacol. Biochem. and Behav., 51 (4), 611-616.
16. Schofield, K. C., McFarland, J. S., Hayflick, J. N., Wilcox, T. M., Cho, S., Roy, N. M., Lee, H. H. and Loh, P. H., Seeburg (1989). Molecular characterization of a new immunoglobulin superfamily protein with potential roles in opioid binding and cell contact. EMBO J., 8 (2), 489-495.
17. Xi-Xie, G., Miyajima, A. and Goldstein, A. (1992). Expression cloning of cDNA engoding a seven-helix receptor from human placenta with affinity for opioid ligands, Proc. Natl. Acad. Sci. USA, 89, 4124-4128.
18. Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C. and Hirth, C. G. (1992). The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization, Proc. Natl. Acad. Sci. USA, 89, 12048-12052.
19. Evans, C. J., Keith, D. E., Jr., Morrison, H., Magendzo, K. and Edwards, R. H. (1992). Cloning of a delta opioid receptor by functional expression, Science, 258, 1952-1955.
20. Reisine, T. (1995). review: Neurotransmitter Receptors V - Opiate Receptors, Neuropharmacol., 34 (5), 463-472.
21. Satoh, M. and Minami, M. (1995). Molecular pharmacology of the opioid receptors, Pharmac. Ther., 68 (3), 343-364.
22. Raynor, K., Kong, H., Chen, Y., Yasuda, K., Yu, L., Bell, G. I. and Reisine, T. (1994). Pharmacological characterization of the cloned κ-, δ- and μ-opioid receptors, Mol. Pharmacol., 45, 330-334.
23. Simonin, F., Befort, K., Gaveriaux-Ruff, C., Matthes, H., Nappey, V., Lannes, B., Micheletti, G. and Kiefer, B. (1994). The human δ-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain, Mol. Pharmacol., 46, 1015-1021.
24. Law and Reisine, T. (1994). Changes in the association of G protein subunits with the cloned mouse delta opioid receptor upon agonist stimulation, Molecular Biol. Cell, 5, 2737.
25. Jin, W., Lee, N. M., Loh, H. and Thayer, S. A. (1992). Dual excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma X glioma hybrid NG 108-15 cells, Mol. Pharmacol., 42, 1083-1089.
26. North, Opioid actions on membrane ion channels. In: Opioid I, vol. 104, Handbook of Experimental Pharmacology, pp 773-797, Herz A. (ed), Springer-Verlag, Berlin.
27. 2+ channel and adenylyl cyclase inhibition by cloned μ- and δ-opioid receptors. INRC 1995 St. Andrews, W59.
28. Tsu, R. C., Chan, J. S. C. and Wong, Y. H. (1995). Regulation of multiple effectors by the cloned δ-opioid receptor: stimulation of phospholipase C and type II adenyl cyclase, J. Neurochem., 64, 2700-2707.
29. Sharif, N. A. and Hughes, J. (1989). Discrete mapping of brain mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors, Peptides, 10, 499-522.
30. Mansour, A., Thompson, R. C., Akil, H. and Watson, S. J. (1993). Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA, J. Chem. Neuroanat., 6, 351-362.
31. Mansour, A., Fox, C. A., Akil, H. and Watson, S. J. (1995). Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications, Trends Neurosci., 18, 22-29.
32. LeMoine, C., Kieffer, B., Gaveriaux-Ruff, C., Befort, K. and Bloch, B. (1994). Delta opioid receptor gene expression in the mouse forebrain: localization in cholinergic neurons on the striatum, Neurosci., 62, 635-640.
33. Stein, C. (1993). Peripheral machanisms of opioid analgesia, Anest. Analg., 76, 182-191.
34. Mosberg, H. I., Hurst, R., Hruby, V. J., Gee, K., Yamamura, H. I., Galligan, J. J. and Burks, T. F. (1983). Bis-penicillamine enkephalins possess highly improved specificity towards delta opioid receptors, Proc. Natl. Acad. Sci. USA, 80, 5871-5874.
35. Delay-Goyet, P., Ruiz-Gayo, M., Baamonde, A., Gacel, G., Morgat, J. L. and Roques, B. P. (1991). Brain passage of BUBU, a highly selective and potent agonist for delta opioid receptors: in vivo binding and mu versus delta receptors occupancy, Pharmacol. Biochem. Behav., 38, 155-162.
36. 2, D-Pen Jenkephalin in the mouse, J. Pharm. Exp. Ther., 241 (2), 393-400.
37. Galligan, J. J., Mosberg, H. I., Hurst, R., Hruby, V. J. and Burks, T. F. (1984). Cerebral delta opioid receptors mediate analgesia but not the intestinal motility effects of intracerebroventricularly administered opioids, J. Pharm. Exp. Ther., 229 (3), 641-648.
38. Heyman, J. S., Mulvaney, S. A., Mosberg, H. I. and Porreca, F. (1987). Opioid δ-receptor involvement in supraspinal and spinal antinociception in mice. Brain res., 420, 100-108.
39. 5]enkaphalin induced analgesia in the jimpy mouse: in vivo evidence for δ-receptor mediated analgesia, Eur. J. Pharm., 136, 405-407.
40. Heyman, J. S., Vaught, J. L., Raffa, R. B. and Porreca, F. (1988). Can supraspinal δ-opioid receptors mediate antinociception?, TIPS, 9, 134-138.
41. Porreca, F., Mosberg, H. I., Omnaas, J. R., Burks, T. F. and Cowan, A. (1987)(b). Supraspinal and spinal potency of selective opioid agonists in the mouse writhing test, J. Pharm. Exp. Ther., 240 (3), 890-694.
42. Borgbjerg, F. M., Frigast, C., Madsen, J. B. and Mikkelsen, L. F. (1996). The effect of intrathecal opioid receptor agonists on visceral noxious stimulation in rabbits, Gastroenterol., 110, 139-146.
43. Miaskowski, C., Taiwo, Y. O. and Levine, J. D. (1992). Contribution of supraspinal μ- and δ-opioid receptors to antinociception in the rat, Eur. J. Pharmacol., 205, 247-252.
44. Ward, J. and Takemori, A. E. (1983). Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice, J. Pharm. Exp. Ther., 224 (3), 525-530.
45. Schmauss, C. and Yaksh, T. L. (1984). In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a different association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat, J. Pharm. Exp. Ther., 228 (1), 1-12.
46. Chaillet, P., Colaud, A., Fournie'-Zaluski, M. C., Gacel, G., Roques, B. P. and Costentin, J. (1983). Pain control by endogenous enkephalins is mediated by mu opioid receptors, Life Sci., 33, Suppl. I, 685-688.
47. Leander, D., Gesellchen, P. D. and Mendelsohn, L. G. (1986). Comparison of two penicillamine-containing enkephalins: mu, not delta, activity produces-analgesia, Neuropeptides, 8, 119-125.
48. Murray, C. W. and Cowan, A. (1991). Tonic pain perception in the mouse: differential modulation by three receptor-selective opioid agonists, J. Pharm. Exp. Ther., 257 (1), 335-341.
49. Calcagnetti, D. J., Helmstetter, F. J. and Fanselow, M. S. (1988). Analgesia produced by centrally administered DAGO, DPDPE and U50488H in the formalin test, Eur. J. Pharmacol., 153, 117-122.
50. Hong, Y. and Abbott, F. V. (1995). Peripheral opioid modulation of pain and inflammation in the formalin test, Eur. J. Pharmacol., 277, 21-28.
51. Ossipov, M. H., Kovelowski, C. J., Nichols, M. L., Hruby, V. J. and Porreca, F. (1995). Characterization of supraspinal antinociceptive actions of opioid delta agonists in the rat, Pain, 62, 287-293.
52. Onofrio, B. M. and Yaksh, T. L. (1983). Intrathecal delta-receptor ligands produces analgesia in man. Lancet, 1, 1386-1387.
53. 5 enkephalin (DADL) in cancer patients with chronic pain. Seattle Proceedings, 511P.
54. Coombs, D. W., Saunders, R. L., Lachance, D., Savage, S., Ragnarsson, T. S. and Jensen, L. E. (1985). Intrathecal morphine tolerance: use of intrathecal clonidine, DADLE, and intraventricular morphine, Anesthesiol., 62 (3), 358-362.
55. noncomplexed site, J. Pharm. Exp. Ther., 255 (2), 636-641.
56. 2]deltorphin II, a highly selective delta agonist in vivo, Life Sci., 47, PL43-17.
57. Portoghese, P. S., Sultana, M., Nagase, H. and Takemori, A. E. (1988). Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists, J. Med. Chem., 31, 281-282.
58. Portoghese, P. S., Sultana, M. and Takemori, A. E. (1990). Design of peptidomimetic delta opioid receptor antagonists using the message-address concept, J. Med. Chem., 33, 1714-1720.
59. Portoghese, P. S., Nagase, H., Maloney-Huss, K. E., Lin, C. E. and Takemori, A. E. (1991). Role of spacer and address component in peptidomimetic delta opioid receptor antagonists related to naltrindole, J. Med. Chem., 34, 1715-1720.
60. 6]enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes, Pharm. Exp. Ther., 257 (3), 1069-1095.
61. Sofuoglu, M., Portoghese, P. S. and Takemori, A. E. (1991). Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes, J. Pharm. Exp. Ther., 257 (2), 676-680.
62. 2]deltorphin II in mice: evidence for delta receptor subtypes, J. Pharm. Exp. Ther., 258 (2), 583-587.
63. Xu, H., Ni, Q., Jacobson, A. E., Rice, K. C. and Rothman, R. B. (1991). Preliminary ligand binding data for subtypes of the delta opioid receptor in rat brain membranes, Life Sci., 49, PL-141-146.
64. Negri, L., Potenza, R. L., Corsi, R. and Melchiorri, P. (1991). Evidence for two subtypes of delta opioid receptors in rat brain, Eur. J. Pharmacol., 196, 335-336.
65. 3H]DPDPE binding to striatal slices of mice, Life Sci., 53, 1761-1765.
66. 3H]naltrindole binding to delta opioid receptors in mouse brain and mouse vas deferens: evidence for delta opioid receptor heterogeneity, J. Pharm. Exp. Ther., 268, 836-846.
67. Uhl, G. R., Childers, S. and Pasternak, G. (1994). An opiate-receptor gene family reunion, TINS, 17 (3), 89-93.
68. 4]deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeaoxynucleotide to an opioid delta receptor, Life Sci., 55 (2), PL 37-13.
69. Belluzzi, J. D., Grant, N., Garsky, V., Sarantakis, D., Wise, C. D. and Stein, L. (1976). Analgesia induced in vivo by central administration of enkaphalin in rat, Nature, 260, 625-626.
70. (a) Hughes, J. (1975). Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine, Brain Res., 88, 295-296;
71. (b) Hughes, J., Smith, T., Morgan, B. and Fothergill, L. (1975). Purification and properties of enkephalin - the possible endogenous ligand for the morphine receptor, Life Sci., 16, 1753-1758.
72. Schiller, P. W., Nguyen, T. M. D., Maziak, L. and Lemieux, C. (1985). A novel cyclic opioid peptide analog showing high preference for μ-receptors, Biochem. Biophys. Res. Commun., 127, 558-564.
73. Rigaudy, P., Garbay-Jaureguiberry, C., Jaquemin-Sablon, A., Le Pecq, J. B. and Roques, B. P. (1987). Synthesis and binding properties to DNA and to opoiod receptors of enkephalin-ellipticinium conjugates, Int. J. Peptide Protein Res., 30, 347-355.
74. (a) Kosterlitz, H. W., Lord, J. A. H., Paterson, S. J. and Waterfield, A. (1980). Effects of changes in the structure of enkephalins and of narcotic analgesic drugs on their interactions with mu and delta receptors. Br. J. Pharmacol., 68, 333-342.
75. (b) Schultz, R., Wuster, M., Kreuss, H. and Hertz, A. (1980). Selective development of tolerance without dependence in multiple opiate receptors of mouse vas deferens, Nature, 285, 242-243.
76. Gacel, G., Fournié-Zaluski, M. C. and Roques, B. P. (1980). D-Tyr-Ser-Gly-Phe-Leu-Thr, a highly preferential ligand for delta-opiate receptors, FEBS lett., 188, 245-247.
77. Gacel, G., Daugé, V., Breuzé, P., Delay-Goyet, P. and Roques, B. P. (1988). Development of conformationally constrained linear peptides exhibiting a high affinity and pronounced selectivity for delta opioid receptors, J. Med. Chem., 31, 1891-1897.
78. Esparmer, V., Melchiorri, P., Falconiery-esparmer, G., Negri, L., Corsi, R., Severini, C., Barra, D., Simmaco, M. and Kreil, G. (1989). Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites, Proc. Natl. Acad. Sci. USA, 86, 5188-5192.
79. Schwyzer, R. (1977). ACTH: A short introductory review, Ann. N. Y. Acad. Sci., 297, 3-26.
80. (a) Nagase, H., Wakita, H., Kawai, K., Endoh, H., Matsura, H., Tanaka, C. and Takezawa, Y. (1994). Synthese of non-peptidic delta opioid agonists and their structure activity relationships. Jpn. J. Pharmacol., 64 Suppl. I, 35.
81. (b) Knapp, R. J., Landsman, R., Waite, S., Malatynska, E., Varga, E., Haq, W., Hruby, V. J., Roeske, W. R., Nagase, H. and Yamamura, H. I. (1995). Properties of TAN-67, a non-peptidic delta opioid receptor agonist at cloned human delta and mu opioid receptors, Eur. J. Pharmacol., 291, 129-134.
82. Dondio, G., Clarke, G. D., Giardina, G., Petrillo, P., Petrone, G., Ronzoni, S., Visentin, L. and Vecchietti, V. (1995). The role of the 'spacer' in the octahydroisoquinoline series: discovery of SB 213698, a non-peptidic, potent and selective delta opioid agonist, Analgesia, 1, 4-6, 394-399.
83. Porreca, F., Mosberg, H., Chang, K.-J., Takemori, A., Comer, S. and Dykstra, L. Pharmacology of multiple opioid delta receptors. In: NIDA Research Monograph 132, Problems of drug dependence 1992: Proceedings of the 54th annual scientific meeting.
84. Chang, K-J., Rigdon, G. C., Howard, J. L. and McNutt, R. W. (1993). A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86, J. Pharm. Exp. Ther., 267 (2), 852-857.
85. Calderon, Rothman, R. B., Porreca, F., Filippen-Anderson, J. L., McNutt, R. W., Xu, L. E., Smith, L. E., Bilsky, E. J., Davis, P. and Rice, K. C. (1994). Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(αR) - ((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N- diethylbenzylamide (SNC 80): a highly selective non peptide delta opioid receptor agonist, J. Med. Chem., 37, 2125-2128.
86. Wild, K. D., McCormick, J., Bilsky, E. J., Vanderah, T., McNutt, R. W., Chang, K.-J. and Porreca, F. (1993). Antinociceptive action of BW373U86 in the mouse, J. Pharm. Exp. Ther., 267 (2), 858-865.
87. Broadbear, J. H., Negus, S. S., Butelman, E. R., DeCosta, B. R. and Woods, J. H. (1994). Differential effects of systemically-administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacol., 115 (3), 311-319.
88. Craft, R. M., Henley, S. R., Haaseth, R. C., Hruby, V. J. and Porreca, F. (1995). Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration, J. Pharm. Exp. Ther., 275 (3), 1535-1542.
89. Comer, S. D., Hoenicke, E. M., Sable, A. I., McNutt, Ro. W., Chang, K.-J., De Costa, B. R., Mosberg, H. I. and Woods, J. H. (1993). Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice, J. Pharm. Exp. Ther., 267 (2), 888-895.
90. Dykstra, L. A., Schoenbaum, G. M., Yarbrough, J., McNutt, R. and Chang, K.-J. (1993). A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration, J. Pharm. Exp. Ther., 267 (2), 875-882.
91. Tortella, F. C., Robles, L., Mosberg, H. I. and Holaday, J. W. (1984). Electroencephalographic assessment of the role of delta receptors in opioid peptide-induced seizures, Neuropeptides, 5, 231-216.
92. Negus, S. S., Butelman, E. R., Chang, K.-J., DeCosta, B., Winger, G. and Woods, J. H. (1994). Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys, J. Pharm. Exp. Ther., 270 (3), 1025-1034.
93. Butelman, Negus, S. S., Gatch, M. B., Chang, K.-J. and Woods, J. H. (1995). BW373U86, a delta-opioid receptor agonist, reverses bradykinin-induced thermal allodynia in rhesus monkeys, Eur. J. Pharmacol., 277, 285-287.
94. Bilsky, Calderon, S. N., Wang, T., Bernstein, R. N., Davis, P., Hruby, V. J., McNutt, R. W., Rothman, R. B., Rice, K. C. and Porreca, F. (1995). SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist, J. Pharm. Exp. Ther., 273 (1), 359-366.
95. Kamei, Saitoh, A., Ohsawa, M., Suzuki, T., Misawa, M., Nagase, H. and Kasuya, Y. (1995). Antinociceptive effects of the selective non-peptidic δ-opioid receptor agonist TAN-67 in diabetic mice, Eur. J. Pharmacol., 276, 131-135.
96. Kamei, 1994, Iwamoto, Y., Misawa, M., Nagase, H. and Kasuya, Y. (1994). Streptozocin-induced diabetes selectively enhances antinociception mediated by delta1 - but not delta2 - opioid receptors, Life Sci., 55, PL121-126.